These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 23933094)

  • 61. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
    Dadras SS; Cai X; Abasolo I; Wang Z
    Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells.
    Lo S; King I; Alléra A; Klingmüller D
    Toxicol In Vitro; 2007 Apr; 21(3):502-8. PubMed ID: 17218080
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats].
    Jia Y; Cue YG; Wang XD; Wang XH; Tong JS; Ma DZ; Cai RF; Di FS
    Zhonghua Nan Ke Xue; 2005 Jan; 11(1):38-41. PubMed ID: 15704680
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
    Pais P
    Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
    Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status.
    Torres JM; Ruiz E; Ortega E
    Prostate; 2003 Jun; 56(1):74-9. PubMed ID: 12746849
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
    Azzouni F; Mohler J
    Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2.
    Hong GL; Park SR; Jung DY; Karunasagara S; Lee KP; Koh EJ; Cho K; Park SS; Jung JY
    J Ethnopharmacol; 2020 Mar; 250():112446. PubMed ID: 31812646
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.
    Dai C; Chung YM; Kovac E; Zhu Z; Li J; Magi-Galluzzi C; Stephenson AJ; Klein EA; Sharifi N
    Clin Cancer Res; 2017 Oct; 23(20):6351-6362. PubMed ID: 28733443
    [No Abstract]   [Full Text] [Related]  

  • 74. 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
    Délos S; Carsol JL; Fina F; Raynaud JP; Martin PM
    Int J Cancer; 1998 Mar; 75(6):840-6. PubMed ID: 9506528
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Establishment of type II 5alpha-reductase over-expressing cell line as an inhibitor screening model.
    Jang S; Lee Y; Hwang SL; Lee MH; Park SJ; Lee IH; Kang S; Roh SS; Seo YJ; Park JK; Lee JH; Kim CD
    J Steroid Biochem Mol Biol; 2007; 107(3-5):245-52. PubMed ID: 17646096
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.
    Kumar VL; Wahane VD
    Indian J Med Sci; 2008 Apr; 62(4):167-75. PubMed ID: 18445985
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of a novel steroid (PM-9) on the inhibition of 5alpha-reductase present in Penicillium crustosum broths.
    Flores E; Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E
    Steroids; 2003 Mar; 68(3):271-5. PubMed ID: 12628690
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
    di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of dihydrotestosterone in benign prostatic hyperplasia.
    Carson C; Rittmaster R
    Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.
    Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R
    Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.